阿伐曲波帕，（Avatrombopag)20mg
1. Ingredients
The active ingredient in Avatrombopag is Avatrombopag Maleate, an orally administered small molecule drug. Its chemical structure resembles that of thrombopoietin but is not a direct derivative. It works by binding to the thrombopoietin receptor (TPO-R).
2. Pharmacological Effects
Avatrombopag is primarily used for treating the following conditions:
- Thrombocytopenia related to chronic liver disease: In these patients, thrombocytopenia can increase the risk of bleeding during surgery. Avatrombopag helps raise platelet counts, reducing the need for transfusions or other preoperative interventions.
- Chronic immune thrombocytopenia (ITP):ITP is a condition caused by an abnormal immune response, leading to decreased platelet counts. Avatrombopag helps increase platelet production in these patients.
3. Usage Instructions
Avatrombopag is an oral tablet, and the recommended dosage depends on the patient's condition and platelet count:
- For patients with chronic liver disease, treatment typically begins 10-13 days before surgery, with a usual dosage of once daily for 5 days.
- For chronic ITP patients,** the dosage can be adjusted based on platelet levels, with an initial dose typically starting at 20 mg per day.
Avatrombopag can be taken with or without food, and platelet levels should be closely monitored during treatment.
4. Development History
Avatrombopag was initially developed by the biopharmaceutical company Eisai, with Dova Pharmaceuticals continuing its research and clinical trials. In 2018, Avatrombopag received FDA approval for treating thrombocytopenia in patients with chronic liver disease. The core of its development was to find a non-peptide thrombopoietin receptor agonist aimed at increasing platelet production through oral administration.
5. Mechanism of Action
Avatrombopag works by binding to the thrombopoietin receptor (TPO-R), mimicking the action of thrombopoietin, promoting the proliferation and differentiation of megakaryocytes in the bone marrow, thereby increasing platelet production. Unlike endogenous thrombopoietin, Avatrombopag binds at different receptor sites, reducing the risk of potential immune reactions.
6. Drug Summary
Avatrombopag is an oral, non-peptide thrombopoietin receptor agonist, suitable for patients with chronic liver disease and immune thrombocytopenia. By stimulating platelet production, it helps reduce preoperative bleeding risks or alleviate symptoms of immune thrombocytopenia. Compared to similar drugs, Avatrombopag offers the convenience of oral administration and has fewer side effects, making it a favorable option in clinical applications.
